CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) has published a
brochure authored by CVBT co-founder and cardiovascular surgeon Dr.
Thomas Stegmann, titled "Holding a Woman's Heart in My Hands." The
informative booklet addresses the unique medical issues women's heart
disease presents in both diagnosis and treatment, and how
angiogenesis--the growth of new blood vessels in the heart--could be a
new medical therapy to treat this disease, which kills more than
480,000 women a year, according to the American Heart Association.
"Fifteen years ago, I was holding a woman's heart in my hands
during a coronary bypass operation knowing I needed more advanced
medical treatment options to address the special heart issues of a
woman. The responsibility I felt towards her and her family led me to
the discovery of therapeutic angiogenesis and the development of this
drug," stated Dr. Stegmann. "Women's heart disease is the number one
cause of death in women and existing diagnostics and therapies are not
enough. With therapeutic angiogenesis we are introducing a new
potential therapy, which I believe can save many lives. In addition,
many women don't view heart disease as a serious health threat and as
an active supporter of the American Heart Association Go Red for Women
we want to help further educate women about this devastating disease
and its treatment options."
The informative pamphlet will be distributed at the American Heart
Association's Go Red for Women Luncheon, to be held February 27, 2008
at the Four Season's Hotel in Las Vegas, Nevada. Dr. Stegmann will
serve as keynote speaker for the event. The Go Red for Women movement
is helping millions of women understand that heart disease, their
number one cause of death, is largely preventable and they can take
steps to lower their risk. The luncheon will feature activities and
topics aimed to educate women about cardiovascular disease, risk
factors and their heart-health.
In addition, a copy of the pamphlet is available by e-mailing a
request to womensheartdisease@cvbt.com.
CVBT is focused on further developing formulations of the protein
drug candidate, human fibroblast growth factor 1 (FGF-1) that Dr.
Stegmann discovered for severe coronary heart disease. FGF-1 is a
recombinant protein that stimulates new blood vessel growth during a
process known as angiogenesis. Once blood perfusion is established in
the affected areas, patients with cardiovascular diseases can
experience an improved quality of life.
In 2004, Dr. Stegmann published "New Vessels for the Heart:
Angiogenesis as New Treatment for Coronary Heart Disease," which
explained his discovery, the first scientific steps and 13-year
journey that led to current human clinical trials of FGF-1.
CVBT recently announced that the U.S. Food and Drug Administration
(FDA) has allowed the company's Phase II Clinical Protocol for
Coronary Heart Disease trials. The company plans to commence the
international study at 30 Medical Centers in the U.S., Canada and
Europe.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates
with human FGF-1 as their active pharmaceutical ingredient (API) for
diseases characterized by inadequate blood flow to a tissue or organ.
The company has three clinical trials underway with drug candidates to
treat the following medical indications: severe Coronary Heart Disease
(CVBT-141H), dermal wound healing in diabetics (CVBT-141B), and
Peripheral Arterial Disease (CVBT-141C).
This news release contains forward-looking statements that involve
risks and uncertainties. Actual results and outcomes may differ
materially from those discussed or anticipated. For example,
statements regarding expectations for new research, progress with
clinical trials or future business initiatives are forward looking
statements. Factors that might affect actual outcomes include, but are
not limited to, FDA approval of CVBT drug candidates, market
acceptance of CVBT products by customers, new developments in the
industry, future revenues, future expenses, future margins, cash usage
and financial performance. For a more detailed discussion of these and
associated risks, see the company's most recent documents filed with
the Securities and Exchange Commission.
